{
    "doi": "https://doi.org/10.1182/blood.V118.21.1009.1009",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1994",
    "start_url_page_num": 1994,
    "is_scraped": "1",
    "article_title": "Favorable Immune Reconstitution After Nonmyeloablative, T-Cell Replete, HLA-Haploidentical BMT with Post-Transplant Cyclophosphamide ",
    "article_date": "November 18, 2011",
    "session_type": "722. Clinical Allogeneic Transplantation - Acute and Chronic GVHD, Immune Reconstitution II",
    "topics": [
        "cyclophosphamide",
        "human leukocyte antigens",
        "immune reconstitution",
        "t-lymphocytes",
        "transplantation",
        "graft-versus-host disease",
        "t-cell receptor",
        "cd31 antigens",
        "hematologic neoplasms",
        "opportunistic infections"
    ],
    "author_names": [
        "Heather J. Symons",
        "Chimene Kesserwan, MD",
        "Ferdynand Kos, PhD",
        "Christopher J. Thoburn, MsC",
        "Ashley T. Munchel, MD",
        "Wendy Ying, BA",
        "Leo Luznik",
        "Hyam I. Levitsky, MD",
        "Richard J. Jones, MD",
        "Allan D. Hess, PhD",
        "Ephraim J. Fuchs"
    ],
    "author_affiliations": [
        [
            "Johns Hopkins University, Baltimore, MD, USA, "
        ],
        [
            "Johns Hopkins University, Baltimore, MD, USA, "
        ],
        [
            "Johns Hopkins University, Baltimore, MD, USA, "
        ],
        [
            "Johns Hopkins University, Baltimore, MD, USA, "
        ],
        [
            "Johns Hopkins University, Baltimore, MD, USA, "
        ],
        [
            "Johns Hopkins University School of Medicine, Baltimore, MD, USA"
        ],
        [
            "Johns Hopkins University, Baltimore, MD, USA, "
        ],
        [
            "Johns Hopkins University, Baltimore, MD, USA, "
        ],
        [
            "Johns Hopkins University, Baltimore, MD, USA, "
        ],
        [
            "Johns Hopkins University, Baltimore, MD, USA, "
        ],
        [
            "Johns Hopkins University, Baltimore, MD, USA, "
        ]
    ],
    "first_author_latitude": "39.329901299999996",
    "first_author_longitude": "-76.6205177",
    "abstract_text": "Abstract 1009 Delayed immune reconstitution with increased risk of opportunistic infection is a major complication of HLA-haploidentical stem cell transplantation, especially in protocols employing extensive T cell depletion of the graft. Previous studies at our institution with high-dose, post-transplantation Cy (PT/Cy) have reported low rates of non-relapse mortality and serious opportunistic infections. Here we characterize immune reconstitution in fifty-three consecutive hematologic malignancies patients receiving nonmyeloablative conditioning, T cell-replete, HLA-haploidentical bone marrow transplantation (BMT), and graft versus host disease prophylaxis including PT/Cy. Patients with advanced hematologic malignancies (median age 51, range 14\u201371; 5 AML, 2 ALL, 4 MDS, 2 CML, 4 CLL, 1 CMML, 25 NHL, 7 Hodgkins, 3 mantle cell) received Cy 14.5 mg/kg/day IV on days \u22126 and \u22125, fludarabine 30 mg/m2/day IV on days \u22126 to \u22122, 200 cGy of TBI on day -1 and T cell replete bone marrow from donors with a median age of 44 (range 14\u201368). GVHD prophylaxis consisted of Cy (50 mg/kg/day) on days 3 and 4, mycophenolate mofetil for 30 days, and tacrolimus for 6 months. Grafts contained an infused median TNC/kg of 4.1 e 8 (range 2.6\u20136.6 e 8 ), CD3 + /kg 3.6 e 7 (range 1.7\u20136.7e 7 ) and a CD34 + /kg of 3.5e 6 (range 1.4\u20137.0e 6 ). Sustained engraftment of donor cells occurred in 86% of evaluable patients (44/51).The median times to neutrophil (>500/\u03bcL) and platelet recovery (>20,000/\u03bcL) were 17 days (range, 13\u201392 days) and 28 days (range, 13\u2013580 days), respectively. Post-transplantation recovery of lymphocyte subsets is shown in Table 1 and Figure 1 and is notable for the following: 1) The median lymphocyte count at day 30 after transplantation is >180/ml and recovers to over 800/ml by day 60; 2) CD4 + T cell counts recover to a median >120/ml by day 60 and >220/ml by day 180 after transplantation; and 3) recovery of CD31 + recent thymic emigrants and CD45RA + nai\u0308ve T cells is delayed compared to recovery of memory T cells. T cell receptor spectratyping analysis on a subset of 10 patient/donor pairs chosen specifically for having no relapse/no GVHD (n=4), GVHD and no relapse (n=3), or late relapse (n=3) revealed that patients without relapse, GVHD, or recent viral infection had excellent reconstitution of the T cell repertoire to the level of the pre-transplant donor, as early as 6 months post-transplant ( Figure 2 ). CMV specific T cell response using ELISPOT measured on a subset of 17 patients whose donors were reactive to CMV, revealed that donor-derived immunity to CMV returns by Day 60 in about 70% of patients (12/17) ( Figure 3 ). In conclusion, immune reconstitution after non-myeloablative haploidentical T cell replete BMT with PT/Cy compares favorably with other reduced intensity conditioning alternative donor regimens and suggests that PT/Cy selectively preserves pathogen-specific memory T cells necessary to protect against infection. Further correlations of immune reconstitution with specific infectious and overall outcomes are being analyzed. Figure 1 View large Download slide T-, B-, and NK-cell Reconstitution Figure 1 View large Download slide T-, B-, and NK-cell Reconstitution Figure 2 View large Download slide T cell receptor spectratyping Figure 2 View large Download slide T cell receptor spectratyping Figure 3 View large Download slide CMV-specific T cell frequency Figure 3 View large Download slide CMV-specific T cell frequency Table 1. Post-transplantation Lymphocyte Subset Recovery . Median (cells/\u03bcL) (N) . Interquartile range (cells/\u03bcL) . ALC    Donor 1765 (46) 1480\u20132100 Recipient pre-BMT 840 (45) 425\u20131295 Day 30 184 (49) 54\u2013402 Day 60 820 (38) 470\u20131260 Day 180 915 (34) 670\u20131560 Day 365 3060 (22) 820\u20132030 CD3 + CD4 + CD45RA + (nai\u0308ve)    Donor 119 (33) 82\u2013189 Recipient pre-BMT 22 (34) 4\u201338 Day 30 0.33 (35) 0.07\u20131 Day 60 3 (29) 1\u20139 Day 180 11 (23) 5\u201331 Day 365 23 (13) 13\u201392 CD3 + CD4 + CD45RA \u2212 CCR7 + (central memory)    Donor 135 (33) 95\u2013158 Recipient pre-BMT 54 (34) 11\u201379 Day 30 2 (35) 0.5\u201311 Day 60 34 (29) 10\u201379 Day 180 61 (23) 35\u2013117 Day 365 89 (13) 60\u2013122 CD3 + CD4 + CD45RA \u2212 CCR7 \u2212 (effector memory)    Donor 187 (33) 130\u2013245 Recipient pre-BMT 87 (34) 14\u2013134 Day 30 3 (35) 1\u201318 Day 60 59 (29) 14\u2013122 Day 180 102 (23) 43\u2013179 Day 365 142 (12) 64\u2013204 CD3 + CD4 + CD45RA + CD31 + (recent thymic emigrants)    Donor 61 (33) 30\u201397 Recipient pre-BMT 6 (34) 1\u201316 Day 30 0.9 (35) 0.03\u20130.4 Day 60 1 (29) 0.5\u20132 Day 180 4 (23) 1\u201311 Day 365 7 (13) 2\u201312 CD3 + CD4 + Foxp3 +    Donor 28 (33) 23\u201335 Recipient pre-BMT 13 (34) 6\u201324 Day 30 1 (35) 0.1\u20135 Day 60 8 (29) 4\u201316 Day 180 13 (23) 7\u201325 Day 365 14 (13) 7\u201317 . Median (cells/\u03bcL) (N) . Interquartile range (cells/\u03bcL) . ALC    Donor 1765 (46) 1480\u20132100 Recipient pre-BMT 840 (45) 425\u20131295 Day 30 184 (49) 54\u2013402 Day 60 820 (38) 470\u20131260 Day 180 915 (34) 670\u20131560 Day 365 3060 (22) 820\u20132030 CD3 + CD4 + CD45RA + (nai\u0308ve)    Donor 119 (33) 82\u2013189 Recipient pre-BMT 22 (34) 4\u201338 Day 30 0.33 (35) 0.07\u20131 Day 60 3 (29) 1\u20139 Day 180 11 (23) 5\u201331 Day 365 23 (13) 13\u201392 CD3 + CD4 + CD45RA \u2212 CCR7 + (central memory)    Donor 135 (33) 95\u2013158 Recipient pre-BMT 54 (34) 11\u201379 Day 30 2 (35) 0.5\u201311 Day 60 34 (29) 10\u201379 Day 180 61 (23) 35\u2013117 Day 365 89 (13) 60\u2013122 CD3 + CD4 + CD45RA \u2212 CCR7 \u2212 (effector memory)    Donor 187 (33) 130\u2013245 Recipient pre-BMT 87 (34) 14\u2013134 Day 30 3 (35) 1\u201318 Day 60 59 (29) 14\u2013122 Day 180 102 (23) 43\u2013179 Day 365 142 (12) 64\u2013204 CD3 + CD4 + CD45RA + CD31 + (recent thymic emigrants)    Donor 61 (33) 30\u201397 Recipient pre-BMT 6 (34) 1\u201316 Day 30 0.9 (35) 0.03\u20130.4 Day 60 1 (29) 0.5\u20132 Day 180 4 (23) 1\u201311 Day 365 7 (13) 2\u201312 CD3 + CD4 + Foxp3 +    Donor 28 (33) 23\u201335 Recipient pre-BMT 13 (34) 6\u201324 Day 30 1 (35) 0.1\u20135 Day 60 8 (29) 4\u201316 Day 180 13 (23) 7\u201325 Day 365 14 (13) 7\u201317 ALC, absolute lymphocyte count; WBC, white blood cell count; T reg , regulatory T cell View Large Disclosures: Jones: Aldagen: Patents & Royalties."
}